Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466752 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
A Phase 2 study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00466752: Completed Phase 2 study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, sponsored by University of Washington.
NCT00466752 is a Phase 2 study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer that has completed, run by University of Washington. The registered enrollment target is 5 participants, below the 109-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00466752, a Phase 2 study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Studying samples of blood and tumor tissues in the laboratory from patients with prostate cancer may help doctors learn more about changes that occur in DNA after treatment with sorafenib tosylate
Primary Outcome
Determined by changes across transcript profiles, by microarray analysis, in pre- versus post-treatment prostate cancer specimens (minimum 50 day time frame between these). Proportion of patients with complete pathologic response.
Conditions Studied
Interventions
- GENETIC gene expression analysis
- GENETIC microarray analysis
- OTHER immunohistochemistry staining method
- DRUG sorafenib tosylate
- PROCEDURE needle biopsy
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-07-01 |
| Phase | Phase 2 |
What the finished NCT00466752 record still lists
NCT00466752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 109-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00466752 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00466752 about?
NCT00466752 is a clinical study titled "Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer". This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Studyin...
What is the current status of trial NCT00466752?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-12. Estimated completion is 2011-07-01.
What conditions does trial NCT00466752 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage II Prostate Cancer.
What interventions are being tested in trial NCT00466752?
The interventions under investigation include: gene expression analysis (GENETIC), microarray analysis (GENETIC), immunohistochemistry staining method (OTHER), sorafenib tosylate (DRUG), needle biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT00466752?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00466752 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00466752's enrollment target sits among peer trials
5 22nd of 21 the lowest of 21 other Adenocarcinoma of the Prostate trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Prostate trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
COMPLETED · Phase 2
-
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
COMPLETED · Phase 2
-
Enzalutamide in Patients With High-risk Prostate Cancer
COMPLETED · Phase 2
-
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
COMPLETED · Phase 2
-
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia